GSK plc

GSK plc EBITDA per Employee

The EBITDA per Employee of GSK plc (GSK.L) as of Oct 26, 2026 is 83,856.02 GBP. In the previous year, EBITDA per Employee was 60,776.48 GBP — a change of 37.97% (higher).

EBITDA per Employee

83,856.02GBP

YoY

37.97%

Last updated:

EBITDA per Employee of GSK plc is 2025 83,856.02 GBP. EBITDA per Employee of GSK plc was 2024 60,776.48 GBP. It decreases by 37.97% higher compared to the previous year.

The GSK plc EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
85,503.80 GBP
Jan 1, 2019
83,420.15 GBP
Jan 1, 2020
87,789.42 GBP
Jan 1, 2021
58,533.37 GBP
Jan 1, 2022
72,002.64 GBP
Jan 1, 2023
75,106.84 GBP
Jan 1, 2024
60,776.48 GBP
Jan 1, 2025
83,856.02 GBP
The GSK plc EBITDA per Employee history
YEAREBITDA per EmployeeYoY
83,856.02GBP+37.97%
60,776.48GBP-19.08%
75,106.84GBP+4.31%
72,002.64GBP+23.01%
58,533.37GBP-33.33%
87,789.42GBP+5.24%
83,420.15GBP-2.44%
85,503.80GBP+0.30%
85,248.66GBP+16.71%
73,044.46GBP+52.62%
47,860.01GBP-9.43%
52,845.87GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EBITDA per Employee of GSK plc is 83,856.02 GBP in 2025.

EBITDA per Employee of GSK plc changed from 60,776.48 GBP to 83,856.02 GBP, representing a 37.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee GSK plc since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — GSK plc

All Key Metrics — GSK plc